TY - JOUR
T1 - Analysis of B-lymphoid malignancies using allele-specific polymerase chain reaction
T2 - A technique for sequential quantitation of residual disease
AU - Billadeau, D.
AU - Blackstadt, M.
AU - Greipp, P.
AU - Kyle, R. A.
AU - Oken, M. M.
AU - Kay, N.
AU - Van Ness, B.
PY - 1991
Y1 - 1991
N2 - The junctional sequences corresponding to the complementarity determining region 3 (CDR3) of rearranged heavy chain Ig genes can provide allele-specific markers in the detection of B-lymphoid malignancies. Consensus oligonucleotide primers were used to amplify CDR3 regions of rearranged heavy chain alleles in clinical samples from myeloma, acute lymphocytic leukemia, and chronic lymphocytic leukemia patients. From the sequence of the amplified products, allele-specific primers were synthesized and used directly in polymerase chain reaction (PCR) amplification to detect the malignant clone. This method was both highly specific and sensitive to 1 malignant B-cell in a background of 105 normal cells. In addition, parameters that affect the linearity of PCR detection were determined and, by using titrations of malignant target cells to generate standard curves, quantitations of residual malignancies were determined. The application of this method is shown in an analysis of myeloma patients whose marrows were analyzed sequentially during therapy. Allele-specific oligonucleotide-PCR provided a rapid, highly specific and quantitative measure of residual disease, even in patients with clinical parameters indicating complete remission.
AB - The junctional sequences corresponding to the complementarity determining region 3 (CDR3) of rearranged heavy chain Ig genes can provide allele-specific markers in the detection of B-lymphoid malignancies. Consensus oligonucleotide primers were used to amplify CDR3 regions of rearranged heavy chain alleles in clinical samples from myeloma, acute lymphocytic leukemia, and chronic lymphocytic leukemia patients. From the sequence of the amplified products, allele-specific primers were synthesized and used directly in polymerase chain reaction (PCR) amplification to detect the malignant clone. This method was both highly specific and sensitive to 1 malignant B-cell in a background of 105 normal cells. In addition, parameters that affect the linearity of PCR detection were determined and, by using titrations of malignant target cells to generate standard curves, quantitations of residual malignancies were determined. The application of this method is shown in an analysis of myeloma patients whose marrows were analyzed sequentially during therapy. Allele-specific oligonucleotide-PCR provided a rapid, highly specific and quantitative measure of residual disease, even in patients with clinical parameters indicating complete remission.
UR - http://www.scopus.com/inward/record.url?scp=0025833889&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025833889&partnerID=8YFLogxK
U2 - 10.1182/blood.v78.11.3021.3021
DO - 10.1182/blood.v78.11.3021.3021
M3 - Article
C2 - 1954387
AN - SCOPUS:0025833889
SN - 0006-4971
VL - 78
SP - 3021
EP - 3029
JO - Blood
JF - Blood
IS - 11
ER -